Ionis Drug Patent Portfolio
Ionis owns 2 orange book drugs protected by 9 US patents Given below is the list of Ionis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10294477 | Compositions And Methods For Modulating Pkk Expression | 01 May, 2035 | Active |
| US9670492 | Modulation Of Prekallikrein (Pkk) Expression | 28 Aug, 2034 | Active |
| US9127276 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US9181549 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US12509684 | Compositions And Methods For Modulating Apolipoprotein C-Iii Expression | 01 May, 2034 | Active |
| US9163239 | Compositions and methods for modulating apolipoprotein C-III expression | 01 May, 2034 | Active |
| US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations | 14 Feb, 2034 | Active |
| US9315811 | Methods For Modulating Kallikrein (Klkb1) Expression | 21 Oct, 2032 | Active |
| US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression | 27 Apr, 2032 | Active |
Latest Legal Activities on Ionis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ionis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 06 Jan, 2026 | US12509684 |
| Recordation of Patent eGrant | 30 Dec, 2025 | US12509684 |
| Patent eGrant Notification | 30 Dec, 2025 | US12509684 |
| Patent Issue Date Used in PTA Calculation | 30 Dec, 2025 | US12509684 |
| Email Notification | 30 Dec, 2025 | US12509684 |
| Mail Patent eGrant Notification | 30 Dec, 2025 | US12509684 |
| Email Notification | 18 Dec, 2025 | US12509684 |
| Issue Notification Mailed | 17 Dec, 2025 | US12509684 |
| transaction for FDA Determination of Regulatory Review Period | 02 Dec, 2025 | US9163239 |
| Initial letter Re: PTE Application to regulating agency | 04 Nov, 2025 | US10294477 |
| Initial letter Re: PTE Application to regulating agency | 04 Nov, 2025 | US9315811 |
| Initial letter Re: PTE Application to regulating agency | 04 Nov, 2025 | US9670492 |
| Second letter to regulating agency to determine regulatory review period | 27 Oct, 2025 | US9163239 |
| Dispatch to FDC | 23 Oct, 2025 | US12509684 |
| Application Is Considered Ready for Issue | 23 Oct, 2025 | US12509684 |
Ionis's Family Patents
Ionis Drug List
Given below is the complete list of Ionis's drugs and the patents protecting them.
1. Dawnzera (autoinjector)
Dawnzera (autoinjector) is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10294477 | Compositions And Methods For Modulating Pkk Expression |
01 May, 2035
(8 years from now)
| Active |
| US9670492 | Modulation Of Prekallikrein (Pkk) Expression |
28 Aug, 2034
(8 years from now)
| Active |
| US9127276 | Conjugated antisense compounds and their use |
01 May, 2034
(7 years from now)
| Active |
| US9181549 | Conjugated antisense compounds and their use |
01 May, 2034
(7 years from now)
| Active |
| US9315811 | Methods For Modulating Kallikrein (Klkb1) Expression |
21 Oct, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dawnzera (autoinjector)'s drug page
2. Tryngolza (autoinjector)
Tryngolza (autoinjector) is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12509684 | Compositions And Methods For Modulating Apolipoprotein C-Iii Expression |
01 May, 2034
(7 years from now)
| Active |
| US9127276 | Conjugated antisense compounds and their use |
01 May, 2034
(7 years from now)
| Active |
| US9163239 | Compositions and methods for modulating apolipoprotein C-III expression |
01 May, 2034
(7 years from now)
| Active |
| US9181549 | Conjugated antisense compounds and their use |
01 May, 2034
(7 years from now)
| Active |
| US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
14 Feb, 2034
(7 years from now)
| Active |
| US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression |
27 Apr, 2032
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tryngolza (autoinjector)'s drug page